Vancomycin
Active ingredient · 3 therapeutic classes
Sold as VANCOCIN
- Drug class
- Antibiotics
- Availability
- Prescription only
- Routes
- Intravenous, Oral
- Markets covered
- 3
- Products on record
- 72
Overview
Vancomycin is an active pharmaceutical ingredient in the Antibiotics group (A07AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 35 | April 10, 2026 |
| GB United Kingdom | MHRA | 31 | May 22, 2026 |
| US United States | FDA | 6 | January 30, 2026 |
CACanada· Health Canada
35 products
Uses
VANCOCIN® (vancomycin hydrochloride capsules) is indicated for: • The treatment of infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions: o staphylococcal enterocolitis, and o antibiotic associated pseudomembranous colitis produced by Clostridium difficile Parenteral administration of vancomycin is not effective for the indicated conditions; therefore VANCOCIN® must be given orally.
VANCOCIN® is not effective by the oral route for the treatment of other types of infection. 1 Pediatrics Pediatrics (premature neonates and young infants): Evidence from clinical studies and experience suggests that use in premature neonates and young infants are associated with differences in safety and a brief discussion can be found in the Warnings and Precautions section.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VANCOCIN® and other antibacterial drugs, VANCOCIN® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
GBUnited Kingdom· MHRA
31 products
Uses
1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
USUnited States· FDA
6 products
Uses
INDICATIONS AND USAGE
Vancomycin Hydrochloride for Injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.
Vancomycin Hydrochloride for Injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin Hydrochloride for Injection, USP is effective in the treatment of staphylococcal endocarditis.
Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures.
Drug interactions
Known interactions involving Vancomycin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 432. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00788716 · revised March 22, 2025
- [2]MHRA (UK) · PL178150042 · revised October 25, 2024
- [3]FDA DailyMed · 00946db3-d6c5-45… · revised January 30, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.